Advertisement

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization

  • Sharmila DorbalaEmail author
  • Yukio Ando
  • Sabahat Bokhari
  • Angela Dispenzieri
  • Rodney H. Falk
  • Victor A. Ferrari
  • Marianna Fontana
  • Olivier Gheysens
  • Julian D. Gillmore
  • Andor W. J. M. Glaudemans
  • Mazen A. Hanna
  • Bouke P. C. Hazenberg
  • Arnt V. Kristen
  • Raymond Y. Kwong
  • Mathew S. Maurer
  • Giampaolo Merlini
  • Edward J. Miller
  • James C. Moon
  • Venkatesh L. Murthy
  • C. Cristina Quarta
  • Claudio Rapezzi
  • Frederick L. Ruberg
  • Sanjiv J. Shah
  • Riemer H. J. A. Slart
  • Hein J. Verberne
  • Jamieson M. Bourque
EXPERT CONSENSUS RECOMMENDATIONS

Abstract

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.

Keywords

Cardiac amyloidosis Diagnosis Appropriate use Expert consensus Multimodality 

Abbreviations

AL

Amyloid immunoglobulin light chains

ATTR

Amyloid transthyretin

DPD

99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid

EF

Ejection fraction

HMDP

Hydroxymethylenediphosphonate

LV

Left ventricular

PYP

Pyrophosphate

Tc

99mTechnetium

Notes

Acknowledgments

We would like to thank the reviewers of this document for their input, which has significantly improved the quality of this document, including Renée P. Bullock-Palmer, MD, FACC, FASNC, FASE, FSCCT; Dennis A. Calnon, MD, FASNC; Marcelo F. Di Carli, MD; Martha Grogan, MD; Phillip Hawkins, PhD, FMedSci; Wael A. Jaber, MD, FACC, FAHA; Prem Soman, MD, FASNC; James E. Udelson, MD, FACC; Ashutosh D. Wechalekar, DM, MRCP, FRCPath.

References

  1. 1.
    Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.CrossRefGoogle Scholar
  2. 2.
    Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 2016;68:1323-41.CrossRefGoogle Scholar
  3. 3.
    Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300.CrossRefGoogle Scholar
  4. 4.
    Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6:34-9.CrossRefGoogle Scholar
  5. 5.
    Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87.CrossRefGoogle Scholar
  6. 6.
    Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 2018;72:2040-50.CrossRefGoogle Scholar
  7. 7.
    Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014-20.CrossRefGoogle Scholar
  8. 8.
    Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging 2018.Google Scholar
  9. 9.
    Fitch KB, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user’s manual (MR-1269-DG-XII/RE). Santa Monica, California: RAND; 2001.Google Scholar
  10. 10.
    Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, et al. ACCF proposed method for evaluating the appropriateness of cardiovascular Imaging J Am Coll Cardiol 2005;46:1606-13.CrossRefGoogle Scholar
  11. 11.
    Aortic Stenosis Writing G, Bonow RO, Brown AS, Gillam LD, Kapadia SR, Kavinsky CJ, et al. ACC, AATS, AHA, ASE, EACTS, HVS, SCA, SCAI, SCCT, SCMR, STS, 2017 appropriate use criteria for the treatment of patients with severe aortic stenosis: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Valve Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Soc Echocardiogr 2018;2018(31):117-47.Google Scholar
  12. 12.
    Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014;63:380-406.CrossRefGoogle Scholar
  13. 13.
    American College of Cardiology Foundation Appropriate Use Criteria Task F, American Society of E, American Heart A, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr 2011;24:229-67.Google Scholar
  14. 14.
    Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986;2:53-63.CrossRefGoogle Scholar
  15. 15.
    Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 appropriate use criteria for multimodality imaging in valvular heart disease: a report of the american college of cardiology appropriate use criteria task force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2017;70:1647-72.CrossRefGoogle Scholar
  16. 16.
    Rybicki FJ, Udelson JE, Peacock WF, Goldhaber SZ, Isselbacher EM, Kazerooni E, et al. 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS appropriate utilization of cardiovascular imaging in emergency department patients with chest pain: a joint document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force. J Am Coll Cardiol 2016;67:853-79.CrossRefGoogle Scholar
  17. 17.
    Hendel RC, Patel MR, Allen JM, Min JK, Shaw LJ, Wolk MJ, et al. Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation appropriate use criteria task force. J Am Coll Cardiol 2013;61:1305-17.CrossRefGoogle Scholar
  18. 18.
    Patel MR, White RD, Abbara S, Bluemke DA, Herfkens RJ, Picard M, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. J Am Coll Cardiol 2013;61:2207-31.CrossRefGoogle Scholar
  19. 19.
    Amis ES Jr, Butler PF, Applegate KE, Birnbaum SB, Brateman LF, Hevezi JM, et al. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol 2007;4:272-84.CrossRefGoogle Scholar
  20. 20.
    Bernstein SJ, Hofer TP, Meijler AP, Rigter H. Setting standards for effectiveness: a comparison of expert panels and decision analysis. Int J Qual Health Care 1997;9:255-63.Google Scholar
  21. 21.
    Kuntz KM, Tsevat J, Weinstein MC, Goldman L. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. JAMA 1999;282:2246-51.CrossRefGoogle Scholar
  22. 22.
    Rowczenio D, Wechalekar, A mutations in hereditary amyloidosis; 2015.Google Scholar
  23. 23.
    Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.CrossRefGoogle Scholar
  24. 24.
    Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7.CrossRefGoogle Scholar
  25. 25.
    Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-7.CrossRefGoogle Scholar
  26. 26.
    Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-95.CrossRefGoogle Scholar
  27. 27.
    Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.CrossRefGoogle Scholar
  28. 28.
    Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood 2018;131:163-73.CrossRefGoogle Scholar
  29. 29.
    Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30.CrossRefGoogle Scholar
  30. 30.
    Dolgin MAN, Fox AC, Gorlin R, Levin RI. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels/the Criteria Committee of the New York Heart Association. Boston, MA: Lippincott Williams and Wilkins; 1994.Google Scholar
  31. 31.
    Criteria Committee NYHA, Inc. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis. Boston: Little, Brown and Co. 1964, p. 114.Google Scholar
  32. 32.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327.Google Scholar
  33. 33.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:2440-92.CrossRefGoogle Scholar
  34. 34.
    American College of Cardiology Foundation Task Force on Expert Consensus D, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;121:2462-508Google Scholar
  35. 35.
    Keith MW, Masear V, Chung KC, Maupin K, Andary M, Amadio PC, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on diagnosis of carpal tunnel syndrome. J Bone Joint Surg Am 2009;91:2478-9.CrossRefGoogle Scholar
  36. 36.
    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.CrossRefGoogle Scholar
  37. 37.
    Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid 2018;25:139-40.CrossRefGoogle Scholar
  38. 38.
    Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid 2017;24:226-30.CrossRefGoogle Scholar
  39. 39.
    Kawel N, Turkbey EB, Carr JJ, Eng J, Gomes AS, Hundley WG, et al. Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging 2012;5:500-8.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology, Heart Failure Society of America, and American Heart Association 2019

Authors and Affiliations

  • Sharmila Dorbala
    • 1
    Email author
  • Yukio Ando
    • 2
  • Sabahat Bokhari
    • 3
  • Angela Dispenzieri
    • 4
  • Rodney H. Falk
    • 1
  • Victor A. Ferrari
    • 5
  • Marianna Fontana
    • 6
  • Olivier Gheysens
    • 7
  • Julian D. Gillmore
    • 6
  • Andor W. J. M. Glaudemans
    • 8
  • Mazen A. Hanna
    • 9
  • Bouke P. C. Hazenberg
    • 10
  • Arnt V. Kristen
    • 11
  • Raymond Y. Kwong
    • 1
  • Mathew S. Maurer
    • 3
  • Giampaolo Merlini
    • 12
    • 13
  • Edward J. Miller
    • 14
  • James C. Moon
    • 6
  • Venkatesh L. Murthy
    • 15
  • C. Cristina Quarta
    • 6
  • Claudio Rapezzi
    • 16
  • Frederick L. Ruberg
    • 17
  • Sanjiv J. Shah
    • 18
  • Riemer H. J. A. Slart
    • 8
  • Hein J. Verberne
    • 19
  • Jamieson M. Bourque
    • 20
  1. 1.Cardiac Amyloidosis Program, Cardiovascular Imaging Program, Departments of Radiology and MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Department of Neurology, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan
  3. 3.Columbia University Medical Center, Columbia University Medical Center/New York Presbyterian HospitalColumbia UniversityNew YorkUSA
  4. 4.Divisions of Hematology and Cardiovascular Diseases, Department of Radiology, Division of Nuclear Medicine, Department of MedicineMayo ClinicRochesterUSA
  5. 5.Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  6. 6.Division of Medicine, National Amyloidosis CentreUniversity College LondonLondonUnited Kingdom
  7. 7.Nuclear Medicine and Molecular ImagingUniversity Hospitals LeuvenLeuvenBelgium
  8. 8.Medical Imaging Center, Department of Nuclear Medicine and Molecular ImagingUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands
  9. 9.Department of Cardiovascular MedicineCleveland ClinicClevelandUSA
  10. 10.Department of Rheumatology & Clinical ImmunologyUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands
  11. 11.Department of CardiologyUniversity of HeidelbergHeidelbergGermany
  12. 12.Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San MatteoPaviaItaly
  13. 13.Department of Molecular MedicineUniversity of PaviaPaviaItaly
  14. 14.Cardiovascular MedicineYale University School of MedicineNew HavenUSA
  15. 15.Frankel Cardiovascular Center, Michigan MedicineAnn ArborUSA
  16. 16.Cardiology Unit, Department of Experimental, Diagnostic and Specialty MedicineAlma Mater-University of BolognaBolognaItaly
  17. 17.Amyloidosis Center and Section of Cardiovascular Medicine, Department of Medicine, Boston University School of MedicineBoston Medical CenterBostonUSA
  18. 18.Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  19. 19.Department of Radiology and Nuclear MedicineAmsterdam UMC, University of AmsterdamAmsterdamThe Netherlands
  20. 20.Cardiovascular Imaging Center, Departments of Medicine and RadiologyUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations